The Dose-Response Associations of Sugar-Sweetened Beverage Intake with the Risk of Stroke, Depression, Cancer, and Cause-Specific Mortality: A Systematic Review and Meta-Analysis of Prospective Studies

Yuanxin Wang, Renqing Zhao *, Bin Wang, Chen Zhao, Baishu Zhu and Xin Tian

Department of Sports and Health Science, College of Physical Education, Yangzhou University, Yangzhou 225009, China; wangyuanxin880330@163.com (Y.W.); bwang1999@126.com (B.W.); zc072866@outlook.com (C.Z.); baishuzhu@outlook.com (B.Z.); tianxin96331@163.com (X.T.)

* Correspondence: renqing.zhao@yzu.edu.cn; Tel.: +86-51487972015

Abstract: The associations between sugar-sweetened beverage (SSB) consumption and the risk of stroke, depression, cancer, and cause-specific mortality have not been determined, and the quantitative aspects of this link remain unclear. This meta-analysis therefore conducted a systematic review and dose-response analysis to determine their causal links. The database searches were conducted in PubMed, Cochrane library, Embase, Web of Science up to 10 November 2021. The intervention effects were evaluated by relative risk (RR) with 95% confidence (CI). Thirty-two articles met the inclusion criteria. Higher levels of SSB consumption significantly increased the risk of stroke (RR 1.12, 95% CI 1.03–1.23), depression (1.25, 1.11–1.41), cancer (1.10, 1.03–1.17), and all-cause mortality (1.08, 1.05–1.11) compared with none or lower SSB intake. The associations were dose-dependent, with per 250 mL increment of SSB intake daily increasing the risk of stroke, depression, cancer, and all-cause mortality by RR 1.09 (1.03–1.15), 1.08 (1.06–1.10), 1.17 (1.04–1.32), and 1.07 (1.03–1.11), respectively. The link was curved for depression and cancer risk ($p_{\text{non-linear}} < 0.05$). Subgroup analysis suggested that higher SSB intake increased ischemic stroke by 10%, CVD-caused mortality by 13%, and cancer-caused mortality by 6.0% than none or lower SSB consumption. It is suggested that SSB accounts for a leading risk factor of stroke, depression, cancer, and mortality, and that the risk rises in parallel with the increment of SSB intake (and is affected by participant characteristics).

Keywords: sugar-sweetened beverage; stroke; depression; cancer; mortality

1. Introduction

Although there is a decline in intake from sugar-sweetened beverages (SSB) in the US and Europe [1,2], the prevalence of SSB consumption worldwide remains very high [3]. SSB is considered as a leading source of energy intake. For example, SSB contributes about 9.3% of daily calories in men and 8.2% in women in US [4,5], and has been linked with weight gain, diabetes, hypertension, hyperlipidemia, gout, and coronary artery diseases (CAD) [6–8]. Presently, more and more people show their concerns about the effects of SSB on health.

SSB intake has been recognized to induce hyperglycemia, dyslipidemia, inflammation, and endothelial dysfunction [9–11], which are assumed as risk factors for stroke. Recently, several studies reported higher SSB consumption increased stroke incidence [12,13]. Additionally, SSB intake often leads to obesity and type 2 diabetes mellitus (T2DM), which are considered as the risk factors of cancer [9,14,15], and evidence from observational studies suggested that there exited a close link between SSB and pancreatic cancer [16,17], breast cancer [17], colorectal cancer [18], and other cancers [19]. The SSB intake is also suspected to increase the risk of depression, and higher depression prevalence was observed among...
greater SSB drinkers both in prospective and cross-sectional studies [20–22]. Given the fact that SSB intake increases chronic diseases, such as stroke, cancer, diabetes, CVD, and hypertension, it subsequently increases mortality risk. It has been estimated that the consumption of SSB are associated with 184,000 deaths annually worldwide [23]. Recently, two large prospective studies observed a higher prevalence of all-cause mortality among greater SSB drinkers [24,25].

However, some important questions remain unaddressed yet. Firstly, the causal relation between SSB intake and chronic diseases has not been established because studies have reported inconsistent results on the associations of SSB with cancer [16,26] or stroke [27,28]. Secondly, although previous meta-analyses reported the relations between SSB and risk of depression and cancer [29,30], the conclusions were drawn by incorporating case or cross-sectional studies, suggesting that the evidence was not substantial and convincing. Up to now, the cause-specific mortality risk related to SSB intake has not been determined [31], and new prospective studies have been reported since previous reviews [25,32,33]. Additionally, the quantified aspects of the associations between SSB intake and chronic diseases have not been determined yet. To address those concerns, we conducted a meta-analysis of cohort studies to determine the associations between SSB intake and the risk of stroke, depression, cancer, and mortality. The quantified aspects of this link and effects of the types of diseases and participant age, body mass index (BMI), total energy (TE) intake, location, and follow-up on the relation were also determined.

2. Materials and Methods

2.1. Search Strategies and Inclusion Criteria

This systematic review and meta-analysis adhered to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [34]. Two authors, BZ and BW, conducted the electronic database searches in PubMed, Cochrane library, EMBASE, and Web of Science using a predetermined protocol up to 10 November 2021. After the removal of duplicates, the articles were screened on the basis of the titles and abstracts, and another author, CZ, reviewed them independently. The full-text of articles then were drawn and reviewed for eligibility independently by BZ and BW. To identify unpublished (ongoing or completed) studies, the WHO International Clinical Trials Registry Platform (ICTRP) search portal and ClinicalTrials.gov were searched up to 10 November 2021. The reference lists of relevant systematic reviews were screened manually to identify further potentially relevant citations. No language restriction was applied. The search strategies for electronic databases are listed in Supplementary Text S1.

The eligible studies should meet the following criteria: (1) prospective cohort studies; (2) the exposure was SSB intake, and the outcomes were incidents of stroke, depression, cancer, or mortality; (3) the participants were healthy adults at enrollment and aged ≥ 18 years; (4) for dose-response analysis, the levels of SSB consumption should be ranked at least three categories. We excluded case or cross-sectional studies, and studies conducted among children were also excluded.

2.2. Data Extraction

Two authors (BZ and BW) independently extracted data from each included study and resolved any disagreement through discussion with another author (CZ). We contacted the corresponding authors to acquire the relevant information not reported in the original paper. The extracted details included the following items: the name of the first author; the study location; the source and the number of participants; mean or median age of participants; follow-up time; person-years, the events of stroke, depression, cancer and mortality, and adjusted relative risk (RR)/hazard ratio (HR) with 95% confidence (CI) for all categories of SSB consumption; covariates used for adjustment, etc. The data extraction followed the methods recommended by Cochrane Reviewers’ Handbook [35].
2.3. Risk of Bias Assessment

The quality of the included studies was evaluated independently by two authors (BZ and BW) using the Newcastle-Ottawa quality assessment scale assessment tools [36]. The results were discussed among the other authors (CZ and XT) for consensus. This scale assigned a maximum of nine points for each study. The following three broad perspectives are examined: the selection of cohorts (four points); comparability of cohorts (two points); ascertainment of the exposure and outcome of interest (three points). Finally, the score for each included study was listed in a table.

2.4. Statistical Analyses

RR with 95% CI were used to calculate the summary effects by the comparison of the risk of stroke, depression, cancer, and mortality between the highest and the lowest categories of SSB consumption. Fixed- or random-effects models were used according to between-study heterogeneity. The adjusted RR was used to conduct the meta-analysis. If only adjusted HR were given, the HR were designated as the RR. If studies did not report the person-years for each category, it was calculated by multiplying the total person-years by the percentage of populations in each category, or multiplying the number of participants in each category by follow-up years. For the included studies, the reported median or mean dose of SSB consumption in each category was designated as the SSB consumption category.

SSB was considered as the main exposure. SSB was defined as any sweetened beverages, including soda, soft drinks, and sugar sweetened fruit juice, etc., not presented as diet. Doses of SSB reported as a serving/drink, ounce, can, and cup size were converted to milliliters per day for the dose–response meta-analyses. The conversions were in accordance with the definition in the original articles. For studies that did not define the portion size, it was converted by using recommended conversions (1 serving/drink = 250 mL, 1 can = 330 mL, and 1 cup = 200 mL).

Subgroup analysis was conducted to evaluate the intervention effects according to the types of diseases, and participants’ age (<60 years vs. ≥60 years), BMI (<24 kg/m² vs. ≥24 kg/m²), TE intake (<1869 kcal/day vs. ≥1869 kcal/day), location (US vs. not US) and follow-up years (<10 years vs. ≥10 years).

The dose-response meta-analysis was performed applying the methods described by Greenland and Longnecker [37], and the study-specific slopes (linear trends), and 95% CI were calculated from the natural logs of the RR and 95% CI across categories. The potential non-linear dose-response associations of diseases with SSB consumptions were estimated by using fractional polynomial models to build a four-knot restricted cubic spline regression. The heterogeneity across studies was determined by Q value (with a significant level at \( p < 0.10 \)) and \( I^2 \) (low: \( I^2 < 30\% \), moderate: \( 30\% \leq I^2 < 60\% \), and high: \( I^2 \geq 60\% \)). A two-tailed \( p \)-value < 0.05 was considered significant. All statistical analyses were performed using STATA software (Version 15, StataCorp LP, College Station, TX, USA).

2.5. Sensitivity and Publication Bias Analyses

To conduct the sensitivity analysis, we determined the associations of SSB consumption with stroke, depression, cancer, and mortality risk by dropping single study and repeating the meta-analysis. To examine the publication bias or other sources of bias, funnel plots were constructed with treatment effects estimated from individual studies against a measure of study size (standard error of RR). Egger’s regression was used to explore the likelihood of the presence of small-study effects.

3. Results

3.1. Study Selection and Characteristics of Included Studies

The electronic database searches identified and screened 8839 abstracts, of which 8743 were excluded due to either duplicate study (n = 3351) or unrelated to the topic (n = 5392). Totally, 102 full-text articles were reviewed for eligibility and 70 were excluded with
reasons: (1) not reporting data of interest (n = 10); (2) not prospective cohort studies (n = 25); (3) duplicate publication (n = 5); (4) not proper exposure (n = 19); and (5) others (n = 11). We identified unpublished information on 11 studies, but those registered studies did not meet eligibility criteria (Table 1). Finally, thirty-two studies were eligible for meta-analysis (Figure 1, Table 1, Supplementary Text S2).

Details are presented in the characteristics of included studies (Table 1). Briefly, 32 reports from 28 cohorts included 3,505,329 participants and reported 13,485 stroke events, 14,166 cancer, 23,694 depression, and 99,126 death, with median follow-up of 14 years. The included studies were conducted in Australia (1 studies), US (17 studies), UK (2 studies), Japan (2 studies), Singapore (2 studies), France (1 studies), Spain (2 studies), Sweden (3 studies), and Europe (2 studies) (Table 1).

3.2. SSB Consumption and Risk of Stroke

Seven cohorts generating eight study groups were included for the analysis of relationship between SSB intake and stroke [12,13,26,28,38,39]. The eligible studies included 350,684 participants and reported 13,483 stroke cases, with a median follow-up of 18 years and 97,903 person-years. Two types of stroke were reported, namely ischemic stroke and hemorrhagic stroke. The NOS score of individual studies was marked from 8 to 9 (Table 1). The heterogeneity between studies were low ($I^2 = 29.9\%$) (Supplementary Table S1). Summary analysis comparing the highest with the lowest categories of SSB consumption indicated that SSB intake significantly increased the risk of all-type stroke by 12% (RR 1.12, 95% CI 1.03–1.23) (Figure 2). We then re-analyzed effect estimates by stratifying stroke types and found that SSB consumption increased ischemic stroke by 10.0% (1.10, 1.01–1.20), but the estimates of effects were not significant for hemorrhagic stroke (6.0% (1.06, 0.92–1.22) (Figure 3). Subgroup analysis also suggested that the intervention effects tended to be significant for participants with age $\geq$ 60 years, BMI $\geq$ 24 kg/m$^2$, TE $\geq$ 1869 kcal/day, living in US, and follow-up $\geq$ 10 years (Figure 3). Dose-response analysis demonstrated that each 250 mL increment of SSB intake daily increased the risk of all-type stroke by RR 1.09 (1.03–1.15) (Figure 4). The likelihood of the presence of publication bias was estimated by constructing funnel plots and examining Egger’s regression test. It is indicated that funnel plots are relatively symmetry (Supplementary Figure S1), and there has weak evidence for the presence of small-study effects (Egger’s test, $p = 0.495$) (Supplementary Figure S1). Sensitivity analysis indicated that the results were still significant after dropping a single study and re-examining effects estimates (Supplementary Table S2).

3.3. SSB Consumption and Risk of Cancer

Fifteen cohort studies were eligible for the analysis of relationship between SSB consumption and cancer [16–19,27,40–49]. The included studies enrolled 1,918,066 participants and reported 1416 cancer cases, with a median follow-up of 14 years and 677,267 person-years. Seven types of cancer were reported, i.e., pancreatic cancer, prostate cancer, glioma, endometrial cancer, breast cancer, colorectal cancer, and hepatocellular carcinoma. The NOS score of individual studies was marked from 8 to 9 (Table 1). The heterogeneity between studies were low ($I^2 = 0\%$) (Supplementary Table S1). Summary analysis showed that SSB consumption significantly increased the risk of all types of cancer by 10% (RR 1.10, 1.03–1.17) (Figure 2). The effect estimates were re-analyzed by stratifying cancer types and other participants’ characteristics finding that SSB consumption increased pancreatic cancer by 11.1% (1.11, 0.95–1.30), and all-type cancers for participants with any age (<60 years and $\geq$60 years), BMI (BMI < 24 kg/m$^2$ and BMI $\geq$ 24 kg/m$^2$), TE (TE < 1869 kcal/day and TE $\geq$ 1869 kcal/day), locations (US and not US), and follow-up (<10 years and $\geq$10 years) (Figure 6). Dose-response analysis demonstrated that per 250 mL increment of SSB intake daily increased the risk of all-type cancer by RR 1.17 (1.04–1.32), and the link was curved ($p_{\text{non-linear}} < 0.05$) (Figure 4).
Table 1. Characteristics of included studies.

| Authors                  | Countries | Cohorts        | Follow-Up (yrs) | Participants                                      | Age (yrs)          | Outcomes                      | Events (n) | QS |
|-------------------------|-----------|----------------|-----------------|---------------------------------------------------|--------------------|--------------------------------|------------|----|
| Bernstein, 2012         | US        | HPFS & NHS     | 28/22           | 43,371 men and 84,085 women                       | 40–75 /30–55       | Ischemic and hemorrhagic stroke| 2356; 736  | 8  |
| Eshak, 2012             | Japan     | Prospective study | 18             | 43,139 men and women                             | 40–59              | Ischemic and hemorrhagic stroke| 1047; 672  | 9  |
| Larsson, 2014           | Sweden    | Prospective study | 10.3           | 68,459 adults                                     | 45–83              | Ischemic and hemorrhagic stroke| 1220; 256  | 9  |
| Gardener, 2012          | US        | NOMAS          | 9.8             | 2564 adults                                       | 69                 | Stroke                        | 255        | 6  |
| Pacheco, 2020          | US        | CTS            | 20              | 106,178 women                                     | 52                 | Stroke                        | 5258       | 8  |
| Pase, 2017             | US        | Prospective study | 10             | 2888 Adults                                       | >45                | Ischemic stroke                | 93         | 9  |
| Bao, 2008               | US        | NIH-AARP       | 7.2             | 487,922 men and women                             | 50–71              | Pancreatic cancer              | 1258       | 9  |
| Bassett, 2020          | Australia | MCCS           | 19              | 35,109 men and women                              | 27–76              | All cancers                    | 4789       | 8  |
| Chazelas, 2019         | France    | NutriNet-Santee | 5.1             | 101,257 adults                                     | 42                 | All cancers                    | 2193       | 9  |
| Drake, 2012            | Sweden    | MDC            | 15              | 8128 men                                          | 45–73              | Prostate cancer                | 513        | 9  |
| Holick, 2010           | US        | Prospective study | 14–24          | 183,978 adults                                     | 36–55              | Glioma                         | 335        | 8  |
| Inoue-Choi, 2013       | US        | IWHS           | 14              | 23,039 postmenopausal women                        | 52–71              | Endometrial cancers            | 506        | 8  |
| Larsson, 2006          | Sweden    | SMC & COSM     | 7.2             | 77,797 women and men                              | 45–83              | Pancreatic cancer              | 131        | 9  |
| Makarem, 2018          | US        | FHS            | 20              | 3184 adults                                       | 26–84              | All cancers                    | 565        | 8  |
| Mueller, 2010          | Singapore | Prospective study | 14             | 60,524 adults                                     | 45–74              | Pancreatic cancer              | 140        | 8  |
| Nomura, 2016          | US        | BWHS           | 16              | 49,103 Black Women                                | 21–69              | Breast cancer                  | 1827       | 9  |
| Nothlings, 2007        | US        | Prospective study | 8              | 162,150 adults                                     | 45–75              | Pancreatic cancer              | 434        | 9  |
| Pacheco, 2019         | US        | Prospective study | 20             | 99,798 female teachers and administrators          | 49–56              | Colorectal cancer              | 1318       | 8  |
| Romanos-Nanclores,     | Spain     | SUN            | 2               | 10,713 Spanish females                             | 33                 | Breast cancer                  | 100        | 8  |
| Schernhammer, 2005     | US        | NHS & HPFS     | 20              | 138,158 men and women                             | 30–55              | Pancreatic cancer              | 379        | 9  |
| Stepien, 2016         | Europe    | EPIC           | 11.4            | 477,206 adults                                     | 51–60              | Hepatocellular carcinoma       | 191        | 9  |
| Guo, 2014             | US        | NIH-AARP       | 11              | 263,923 Adults                                    | 50–71              | Depression                     | 11,092     | 9  |
### Table 1. Cont.

| Authors                  | Countries   | Cohorts                | Follow-Up (yrs) | Participants                  | Age (yrs) | Outcomes                     | Events (n) | QS  |
|--------------------------|-------------|------------------------|-----------------|-------------------------------|-----------|-------------------------------|------------|-----|
| Knüppel, 2017 [51]      | UK          | The Whitehall Study II | 5               | 8087 adults                   | 35–55     | Depression                   | 741        | 9   |
| Sanchez-Villegas, 2017 [52] Mortality Anderson, 2020 [32] | Spain       | SUN                    | 10              | 15,546 Spanish university graduates | 25–65     | Depression                   | 769        | 8   |
| Barrington, 2016 [33]   | US          | VITAL                  | 5               | 69,582 adults                 | 50–76     | All-cause mortality          | 1066       | 9   |
| Collin, 2019 [54]       | US          | REGARDS                | 6               | 13,440 adults                 | 64        | CVD- and cancer-caused mortality | 168        | 9   |
| Malik, 2019 [24]        | US          | HPFS                   | 34              | 118,363 men and women         | 40–75     | CVD- and cancer-caused mortality | 7896; 12,380 | 9   |
| Mullee, 2019 [25]       | Europe      | EPIC                   | 16.4            | 451,743 adults                | 51        | CVD- and cancer-caused mortality | 5867; 12,231 | 9   |
| Odegaard, 2015 [55]     | Singapore   | SCHS                   | 16.3            | 52,584 Chinese men and women  | 45–74     | CVD- and cancer-caused mortality | 3097; 3902 | 9   |
| Paganini-Hill, 2007 [56] | US         | Prospective study     | 23              | 13,624 men and women          | 74        | All-cause mortality          | 11,386     | 8   |
| Zhang, 2020 [33]        | US          | NHANES                 | 7.9             | 31,402 adults ≥ 20            | All-cause mortality | 676; 884 | 8   |

Notes: The quality of the included studies was evaluated using the Newcastle-Ottawa quality assessment scale assessment tools. yrs, years; QS, quality score; CVD, cardiovascular diseases.

The likelihood of presence of publication bias was explored by examining funnel plots and analyzing Egger’s test. The funnel plots were somewhat asymmetry (Supplementary Figure S3), and there seemed to exist in evidence for the presence of small-study effects (Egger’s test, \( p = 0.01 \)) (Supplementary Table S1). It was suggested that two studies [27,44] contributed to the potential bias, and after dropping the two studies the estimation of Egger’s test was 0.058. We further examined the effects of the two studies on the intervention effects. The results indicated that the estimates effects were still significant (1.09, 1.03–1.16) after removal of the two studies, suggesting that the results were not affected by the two studies much. Sensitivity analysis was also performed by dropping a single study and re-examining the effects estimates. It is indicated that the results were robust (Supplementary Table S4).

#### 3.4. SSB Consumption and Risk of Mortality

Eight prospective cohorts generating nine study groups were included for determining the associations of SSB intake with mortality [24,25,32,33,53–56]. The eligible studies included 949,023 participants and reported 99,126 deaths, with a median follow-up of 12.1 years and 913,357 person-years. There were two types of mortality, i.e., mortality caused by cardiovascular diseases (CVD) and cancer. The NOS score of the included studies was marked from 8 to 9 (Table 1). The heterogeneity between studies were high (\( I^2 = 68.2\% \)) (Supplementary Table S1) and random-effects methods were used for pooling effects estimates. Summary analysis indicated that SSB intake significantly increased the risk of all-cause mortality by 6\% (RR 1.08, 1.05–1.11) (Figure 2). Subgroup analysis suggested that SSB intake increased both CVD- and cancer-caused mortality (RR 1.13, 1.06–1.20, and 1.06, 1.01–1.12, respectively), and increases all-cause mortality for participants with
any age (<60 years and ≥60 years), BMI (BMI < 24 kg/m² and BMI ≥ 24 kg/m²), TE (TE < 1869 kcal/day and TE ≥ 1869 kcal/day), locations (US and not US), and follow-up (<10 years and ≥10 years) (Figure 7). Dose-response analysis demonstrated that per 250 mL increment of SSB daily increased all-cause mortality risk by RR 1.07 (1.03–1.11) (Figure 4).

Figure 1. Flow chart for the selection of studies.
We then examined the potential source of between-study heterogeneity and its effects on the results. It was suggested that one study [55] might contribute to the main source of heterogeneity since the score of $I^2$ dropped to 47.7% after removal of this study and estimated effects were still significant (RR 1.14, 1.09–1.19). It is indicated that the inclusion of this study did not pose a threat on the stability of our results. The likelihood of presence of publication bias was evaluated by examining funnel plots and conducting Egger’s regression test. It was indicated that the funnel plots were relatively symmetry (Supplementary Figure S4) and there had weak evidence for the presence of small-study effects (Egger test, $p = 0.489$) (Supplementary Table S1). Sensitivity analysis indicated that the results were robust (Supplementary Table S5).

Figure 2. Overall analysis of the associations of sugar-sweetened beverage (SSB) intake with the risk of stroke, depression, cancer, and mortality. The square indicates relative risk (RR) with 95% confidence interval (CI). The rhombus denotes effects sizes.
| Categories of Studies | Studies (n) | Participants (n) | Events (n) | RR (95% CI) |
|-----------------------|-------------|-----------------|------------|-------------|
| Ischemic Stroke       | 4           | 157,857         | 4716       | 1.10 (1.01, 1.20) |
| Hemorrhagic Stroke    | 3           | 155,683         | 1664       | 1.06 (0.92, 1.22) |
| Age                   |             |                 |            |             |
| < 60 years            | 3           | 173,483         | 4904       | 1.10 (0.99, 1.22) |
| ≥ 60 years            | 3           | 73,911          | 1824       | 1.17 (1.01, 1.36) |
| BMI                   |             |                 |            |             |
| < 24 kg/m²            | 1           | 43,139          | 1719       | 0.90 (0.73, 1.12) |
| ≥ 24 kg/m²            | 5           | 204,255         | 5029       | 1.17 (1.07, 1.29) |
| Total Energy Intake Daily |           |                 |            |             |
| < 1869 kcal           | 3           | 173,159         | 5086       | 1.04 (0.91, 1.19) |
| ≥ 1869 kcal           | 3           | 74,255          | 1862       | 1.20 (1.06, 1.35) |
| Location              |             |                 |            |             |
| US                    | 4           | 131,598         | 3195       | 1.17 (1.09, 1.21) |
| Non-US                | 2           | 135,798         | 3533       | 1.08 (0.99, 1.20) |
| Follow-up             |             |                 |            |             |
| < 10 years            | 1           | 2564            | 225        | 1.01 (0.84, 1.18) |
| ≥ 10 years            | 5           | 244,830         | 6473       | 1.13 (1.02, 1.23) |

**Figure 3.** Subgroup analysis of the associations between sugar-sweetened beverage (SSB) intake and stroke stratified by the types of stroke, age, body mass index (BMI), energy intake daily, location, and follow-up years. The square indicates relative risk (RR) with 95% confidence interval (CI).

**Figure 4.** Linear or spline regression of the link between sugar-sweetened beverage (SSB) intake and the risk of stroke, depression, cancer, and mortality. RR: relative risk. CI: confidence interval.
3.3. SSB Consumption and Risk of Depression

Three cohorts generating four study groups were included for determining the associations of SSB consumption with depression stratified by the types of cancer, age, body mass index (BMI), energy intake daily, location, and follow-up years. The square indicates relative risk (RR) with 95% confidence interval (CI).

### Table 1

| Categories of Studies | Studies (n) | Participants (n) | Events (n) | RR (95% CI) |
|-----------------------|------------|-----------------|------------|-------------|
| **Age**               |            |                 |            |             |
| < 60 years            | 2          | 23,633          | 1210       | 1.18 (0.93, 1.49) |
| ≥ 60 years            | 1          | 263,923         | 11,002     | 1.28 (1.12, 1.47) |
| **BMI**               |            |                 |            |             |
| < 24 kg/m²             | 1          | 15,546          | 789        | 1.12 (0.87, 1.45) |
| ≥ 24 kg/m²             | 2          | 272,010         | 11,833     | 1.30 (1.13, 1.48) |
| **Total Energy Intake**|            |                 |            |             |
| < 1869 kcal            | 2          | 272,010         | 11,833     | 1.30 (1.13, 1.48) |
| ≥ 1869 kcal            | 1          | 15,546          | 789        | 1.12 (0.87, 1.45) |
| **Location**           |            |                 |            |             |
| US                    | 1          | 263,923         | 11,002     | 1.28 (1.12, 1.47) |
| Not US                | 2          | 23,633          | 11,061     | 1.18 (0.93, 1.49) |
| **Follow-up**          |            |                 |            |             |
| < 10 years            | 1          | 8697            | 741        | 1.24 (1.10, 1.40) |
| ≥ 10 years            | 2          | 279,469         | 11,861     | 1.60 (0.84, 3.05) |

*Figure 5.* Subgroup analysis of the associations between sugar-sweetened beverage (SSB) intake and depression stratified by age, body mass index (BMI), energy intake daily, location, and follow-up years. The square indicates relative risk (RR) with 95% confidence interval (CI).

### Table 2

| Categories of Studies | Studies (n) | Participants (n) | Events (n) | RR (95% CI) |
|-----------------------|------------|-----------------|------------|-------------|
| **Types of Cancer**   |            |                 |            |             |
| Pancreatic Cancer     | 5          | 926,551         | 2342       | 1.11 (0.95, 1.30) |
| **Age**               |            |                 |            |             |
| < 60 years            | 11         | 1,200,000       | 12,350     | 1.12 (1.06, 1.19) |
| ≥ 60 years            | 4          | 750,908         | 2329       | 1.10 (1.08, 1.14) |
| **BMI**               |            |                 |            |             |
| < 24 kg/m²             | 12         | 172,494         | 2433       | 1.33 (1.17, 1.51) |
| ≥ 24 kg/m²             | 3          | 1,700,000       | 12,246     | 1.10 (1.03, 1.17) |
| **Total Energy Intake**|            |                 |            |             |
| < 1869 kcal            | 5          | 836,264         | 5797       | 1.13 (1.05, 1.21) |
| ≥ 1869 kcal            | 9          | 1,100,000       | 8882       | 1.16 (1.06, 1.27) |
| **Location**           |            |                 |            |             |
| US                    | 8          | 1,100,000       | 6622       | 1.06 (1.01, 1.16) |
| Not US                | 7          | 770,734         | 8057       | 1.03 (1.03, 1.24) |
| **Follow-up**          |            |                 |            |             |
| < 10 years            | 5          | 839,839         | 4116       | 1.24 (1.12, 1.37) |
| ≥ 10 years            | 10         | 1,100,000       | 10,563     | 1.10 (1.03, 1.17) |

*Figure 6.* Subgroup analysis of the associations between sugar-sweetened beverage (SSB) intake and cancer stratified by the types of cancer, age, body mass index (BMI), energy intake daily, location, and follow-up years. The square indicates relative risk (RR) with 95% confidence interval (CI).
3.5. SSB Consumption and Risk of Mortality

Eight prospective cohorts generating nine study groups were included for determining the associations of SSB intake with mortality [24,25,32,33,53–56]. The eligible studies included 949,023 participants and reported 99,126 deaths, with a median follow-up of 12.1 years and 913,357 person-years. There were two types of mortality, i.e., mortality caused by cardiovascular diseases (CVD) and cancer. The NOS score of the included studies was marked from 8 to 9 (Table 1). The heterogeneity between studies were high ($I^2 = 68.2\%$) (Supplementary Table S1) and random-effects methods were used for pooling effects estimates. Summary analysis indicated that SSB intake significantly increased the risk of all-cause mortality by 6% (RR 1.08, 1.05–1.11) (Figure 2). Subgroup analysis suggested that SSB intake increased both CVD- and cancer-caused mortality (RR 1.13, 1.06–1.20, and 1.06, 1.01–1.12, respectively), and increases all-cause mortality for participants with any age (<60 years and $\geq$ 60 years), BMI (BMI < 24 kg/m$^2$ and BMI $\geq$ 24 kg/m$^2$), TE (TE < 1869 kcal/day and TE $\geq$ 1869 kcal/day), locations (US and not US), and follow-up (<10 years and $\geq$ 10 years) (Figure 7). Dose-response analysis demonstrated that per 250 mL increment of SSB daily increased all-cause mortality risk by RR 1.07 (1.03–1.11) (Figure 4).

Figure 7. Subgroup analysis of the associations between sugar-sweetened beverage (SSB) and mortality stratified by cause-specific mortality, age, body mass index (BMI), energy intake daily, location, and follow-up years. The square indicates relative risk (RR) with 95% confidence interval (CI).

4. Discussion

Our study has provided quantified evidence on the associations of SSB consumption with chronic diseases and death, finding that the risk of stroke, depression, cancer, and mortality increased in parallel to the increment of SSB intake. Additionally, the types of diseases and participant age, BMI, TE, location, and follow-up affected the detrimental relations. It is suggested that increasing SSB intake might increase the risks of the incidence of stroke, depression, cancer, and mortality in adults.

The associations of SSB intake with the incidents of stroke have been well-investigated by observational studies [12,39]. However, it remains unclear which types of stroke are mostly affected by SSB consumption. Larsson et al. reported that SSB consumption significantly increased both ischemic and hemorrhagic stroke risk [39], whereas other studies found that the effects were only significant for ischemic stroke [12,38]. Our findings confirm that ischemic stroke is more sensitive to SSB intake. Additionally, the quantified aspects of the link between stroke risk and SSB intake remain undetermined. Our results demonstrated that the incidents of stroke increased in parallel to the doses of SSB consumption. There are several possible causal explanations for this observed association. SSB intake potentially increases metabolic syndrome and its components [6,57,58]. Findings from the randomized controlled trial observed a harmful effect of SSB consumption on low density lipoprotein (LDL) particles, fasting glucose, and high-sensitivity C-reactive protein (CRP) [58]. Another study found that SSB intake was positively associated with plasma triglycerides (TGs), IL-6, and tumor necrosis factor (TNF) receptors, and inversely associated with high density lipoprotein (HDL) cholesterol, lipoprotein, and leptin [57]. SSB intake also has been found to elevate blood glucose and insulin levels, and positively associated with weight gain and T2DM risk [6,59,60]. All of those adverse factors are well-established risk factors for stroke [61,62]. Those adverse factors also explained the findings that higher participant age,
BMI, and TE tended to develop stroke in response to SSB consumptions. It is reported that SSB contributes a leading source of energy intake in US [4,5] indicating that Americans are prone to suffer from the adverse effects SSB consumptions on stroke. The longer follow-up indicated longer exposure of SSB intake for participants which might contribute to positive associations between SSB intake and stroke risk.

The World Cancer Research Fund (WCRF) reports that overweight and obesity are linked to incidents of cancers, such as liver, advanced prostate, ovary, gallbladder, kidney, colorectum, esophagus, postmenopausal breast, pancreas, endometrium, and stomach cancers [63]. SSB intake is currently identified as a leading source for energy intake and a driver for obesity, and studies frequently observed positive associations between higher levels of SSB consumption and incidents of obesity-related cancers [15,45]. Additionally, a recent study reports that SSB intake increases the overall cancers (not obesity cancers only) [19], which indicates that besides obesity other risk factors, such as hyperglycemia, dyslipidemia, inflammation, and hyperinsulinemia [9–11], might contribute to this detrimental link. The results of subgroup analysis seemed to support those reports finding that any age, BMI, TE, location, and follow-up showed positive associations between SSB intake and cancers.

Our study further suggests that the link is dose-dependent indicating that the risk of cancers increases in parallel to the amount of SSB intake. However, a recent meta-analysis found no association between SSB consumption and cancer risks [64]. This meta-analysis did not show the isolated associations in sugary drinks and artificially sweetened beverages, which might have impaired the possibility to detect a potential role of sugar drinks. Actually, a lack of correlation between artificially sweetened beverages and cancers has been frequently reported [15,40]. We did not find a close relation between SSB intake and pancreatic cancer. A previous meta-analysis also failed to find associations between SSB and pancreatic cancer risk [65]. Therefore, it is indicated that other types of cancer might contribute to the correlation between SSB and cancer risk.

The associations between SSB and the risk of cancer might be partly explained by their effect on overweight and obesity [66]. Additionally, SSB drinks also promote gains in visceral adiposity independently of body weight [66,67]. Visceral adiposity could promote tumorigenesis through alterations in adipokine secretion and cell signaling pathways [68]. Other pathways might relate to the high glycemic index or glycemic load of SSB consumption [69], which are recognized to be associated with hyperinsulinemia and type 2 diabetes [70].

The current meta-analysis for the first time provided quantified evidence on the associations between SSB and depression. Although SSB has been suspected of being related to depression risk, the causal link has not been established yet. Firstly, the associations between SSB and depression were frequently determined in cross-sectional studies [71,72]. Secondly, prospective studies have reported inconsistent results. For example, one prospective study within the National Institutes of Health American Association of Retired Persons (NIH–AARP) Diet and Health Study reported a detrimental correlation between SSB intake and depressive risk [30], whereas another cohort study indicated the correlation was not significant [73]. Our meta-analysis, based upon the evidence from prospective studies, ascertained a close link between SSB intake and depression risk. We further demonstrated the correlation is dose-dependent, suggesting that the more SSB is consumed, the more depression might be observed. There was one meta-analysis reporting on the relationship between SSB and depression, but the major evidence was based upon cross-sectional studies and the quantitative aspects of this link were not analyzed [29]. SSB consumption is associated with a variety of socio-economic and lifestyle factors and may contribute to obesity, diabetes, and poor health, which in turn contribute to the development of depression. Obesity has been found to be linked with increased cortisol production and higher hypothalamic–pituitary–adrenal (HPA) axis reactivity to psychological and physiological stress, which may lead to altered endocrine and stress responses [74].

In fact, consumption of added sugars from soft drinks has been linked with several metabolic disturbances such as impaired glucose homoeostasis and insulin resistance [75].
Low concentrations of brain derived neurotrophic factor (BDNF) have been recognized as facilitating neurogenesis and hippocampal atrophy in depression [76]. Rodents fed high-fat high-sugar foods rather than high-fat foods only have a reduction of BDNF levels [77,78], which could be a causal link between SSB consumption and depression. Additionally, sugar consumption has been associated with increased circulating inflammatory markers, which may depress mood [79,80]. Finally, high sugar intakes from soft drinks could induce hypoglycemia through a higher insulin response and thereby affects hormone secretion and potentially mood states [81]. Although the associations between SSB intake and depression seemed to be affected by participant age, BMI, TE, location, and follow-up, the limited studies included for subgroup analysis might not be sufficient to generate definitive conclusions.

Recently, two large prospective studies (i.e., the Health Professionals Follow-up Study (HPFS) and Nurses’ Health Study (NHS) [24] and the European Prospective Investigation into Cancer and Nutrition (EPIC) [25]), reported that a higher level of consumption of SSB was associated with greater all-cause mortality in the United States and ten Europe countries, respectively. Since the consumption of SSB is associated with obesity [31,82], hypertension [83], T2DM [84], CVD [85], stroke [18], and cancer [86], all of which are considered as the leading causes of mortality. It has been estimated that the consumption of SSB were associated with 184,000 deaths annually worldwide: 133,000 from diabetes, 45,000 from CVD, and 6450 from cancer [23]. In accordance with this report are the findings of the subgroup analysis showing that SSB intake increases the risk of CVD- and cancer-caused mortality, and the relationship is significant for higher BMI and any age, TE, and follow-up. Our findings further reveal a dose-dependent association between SSB consumptions and all-cause mortality indicating that the mortality risk elevated with the increment of SSB intake.

The Strength and Limitations

One strength of the present meta-analysis is that only prospective studies were included, which is likely to draw a relative definitive conclusion. On the contrary, the cross-sectional or case studies offer less compelling evidence of possible causal links between SSB and chronic diseases due to the inevitable bias, for example selection bias. Furthermore, our study has determined quantified aspects of the relationship between SSB and the risk of stroke, depression, cancer, and mortality. Additionally, in comparison to previous meta-analysis, our review includes most recent well-designed prospective studies (for example, Anderson et al., 2020 [32]; Mullee et al., 2019 [25]; Zhang et al., 2020 [33]) which provided more valuable information about the relationship between SSB and chronic diseases. However, there exist some limitations of our study, for example for the analysis of the associations between SSB and depression, only three prospective studies were included, and subgroup analysis could be conducted only for pancreatic cancer due to the limited number of studies reporting other types of cancers.

5. Conclusions

Our study demonstrated that the risk of stroke, depression, cancer, and mortality increased in parallel to the increment of SSB consumption. The findings have clinical significance since the risk factors are modifiable, and reduction of SSB consumption helps to prevent some chronic diseases and disease-related mortality. However, well-designed prospective studies are still needed to confirm the findings of our reports and to determine the correlation between SSB consumption and the occurrence of some important chronic diseases, such as dementia and Parkinson’s disease.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nu14040777/s1, Figure S1. Funnel plots for stroke, Figure S2. Funnel plots for depression, Figure S3. Funnel plots for cancers, Figure S4. Funnel plots for mortality, Table S1. Heterogeneity and Egger’s test, Table S2. Sensitivity of stroke, Table S3. Sensitivity of depression, Table S4. Sensitivity of cancer, Table S5. Sensitivity of mortality, Text S1. Search strategies, Text S2. Unpublished studies.
Author Contributions: Conceptualization, R.Z. and Y.W.; methodology, R.Z. and Y.W.; software, B.Z.; validation, B.W. and X.T.; formal analysis, X.T. and B.W.; data curation, C.Z.; writing—original draft preparation, R.Z. and Y.W.; writing—review and editing, R.Z. and Y.W.; supervision, R.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by Natural Science Foundation of Jiangsu Province (BK20201435).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data are reported in this manuscript.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Vercammen, K.A.; Moran, A.J.; Soto, M.J.; Kennedy-Shaffer, L.; Bleich, S.N. Decreasing Trends in Heavy Sugar-Sweetened Beverage Consumption in the United States, 2003 to 2016. J. Acad. Nutr. Diet. 2020, 120, 1974–1985.e5. [CrossRef] [PubMed]

2. Chatelan, A.; Rouche, M.; Dzielska, A.; Lebacq, T.; Fismen, A.-S.; Kelly, C.; Zaborskis, A.; Kopcakova, J.; Tsareva, A.; Kalman, M.; et al. Time trends in consumption of sugar-sweetened beverages and related socioeconomic differences among adolescents in Eastern Europe: Signs of a nutrition transition? Am. J. Clin. Nutr. 2021, 114, 1476–1485. [CrossRef] [PubMed]

3. Popkin, B.M.; Hawkes, C. Sweetening of the global diet, particularly beverages: Patterns, trends, and policy responses. Lancet Diabetes Endocrinol. 2016, 4, 174–186. [CrossRef]

4. Ogden, C.L.; Kit, B.K.; Carroll, M.D.; Park, S. Consumption of sugar drinks in the United States, 2005–2008. NCHS Data Brief 2011, 71, 1–8.

5. Rosinger, A.; Herrick, K.; Gahche, J.; Park, S. Sugar-sweetened Beverage Consumption among U.S. Adults, 2011–2014. NCHS Data Brief 2017, 270, 1–8.

6. Malik, V.S.; Popkin, B.M.; Bray, G.A.; Despres, J.P.; Hu, F.B. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 2010, 121, 1356–1364. [CrossRef]

7. Schulze, M.B.; Manson, J.E.; Ludwig, D.S.; Colditz, G.A.; Stampfer, M.J.; Willett, W.C.; Hu, F.B. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA 2004, 292, 927–934. [CrossRef]

8. Choi, H.K.; Willett, W.; Curhan, G. Fructose-rich beverages and risk of gout in women. JAMA 2010, 304, 2270–2278. [CrossRef]

9. Pase, M.P.; Himali, J.J.; Beiser, A.S.; Aparicio, H.J.; Satzibal, C.L.; Vasan, R.S.; Seshadri, S.; Jacques, P.F. Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study. Stroke 2017, 48, 1139–1146. [CrossRef]

10. Klement, R.J.; Kammerer, U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr. Metab. 2011, 8, 75. [CrossRef]

11. Tamez, M.; Monge, A.; Lopez-Ridaura, R.; Fagherazzi, G.; Rinaldi, S.; Ortiz-Panozo, E.; Yunes, E.; Romieu, I.; Lajous, M. Soda Intake Is Directly Associated with Serum C-Reactive Protein Concentration in Mexican Women. J. Nutr. 2018, 148, 117–124. [CrossRef] [PubMed]

12. Bernstein, A.M.; de Koning, L.; Flint, A.J.; Rexrode, K.M.; Willett, W.C. Soda consumption and the risk of stroke in men and women. Am. J. Clin. Nutr. 2012, 95, 1190–1199. [CrossRef] [PubMed]

13. Pase, M.P.; Himali, J.J.; Beiser, A.S.; Aparicio, H.J.; Satzibal, C.L.; Vasan, R.S.; Seshadri, S.; Jacques, P.F. Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study. Stroke 2017, 48, 1139–1146. [CrossRef] [PubMed]

14. Fisher, W.E.; Boros, L.G.; Schirmer, W.J. Insulin promotes pancreatic cancer: Evidence for endocrine influence on exocrine pancreatic tumors. J. Surg. Res. 1996, 63, 310–313. [CrossRef] [PubMed]

15. Hodge, A.M.; Bassett, J.K.; Milne, R.L.; English, D.R.; Giles, G.G. Consumption of sugar-sweetened and artificially sweetened soft drinks and risk of obesity-related cancers. Public Health Nutr. 2018, 21, 1618–1626. [CrossRef]

16. Bao, Y.; Stolzenberg-Solomon, R.; Jiao, L.; Silverman, D.T.; Subar, A.F.; Park, Y.; Leitzmann, M.F.; Hollenbeck, A.; Schatzkin, A.; Michaud, D.S. Added sugar and sugar-sweetened foods and beverages and the risk of pancreatic cancer in the National Institutes of Health-AARP Diet and Health Study. Am. J. Clin. Nutr. 2008, 88, 431–440. [CrossRef]

17. Romanos-Nanclares, A.; Toledo, E.; Gardeazabal, I.; Jimenez-Moleon, J.J.; Martinez-Gonzalez, M.A.; Gea, A. Sugar-sweetened beverage consumption and incidence of breast cancer: The Seguimiento Universidad de Navarra (SUN) Project. Eur. J. Nutr. 2019, 58, 2875–2886. [CrossRef]

18. Pacheco, L.S.; Anderson, C.A.M.; Lacey, J.V.; Giovannucci, E.L.; Lemus, H.; Araneta, M.R.G.; Sears, D.D.; Talavera, G.A.; Martinez, M.E. Sugar-sweetened beverages and colorectal cancer risk in the California Teachers Study. PLoS ONE 2019, 14, e0223638. [CrossRef]

19. Bassett, J.K.; Milne, R.L.; English, D.R.; Giles, G.G.; Hodge, A.M. Consumption of sugar-sweetened and artificially sweetened soft drinks and risks of cancer not related to obesity. Int. J. Cancer 2020, 146, 3329–3334. [CrossRef]
20. El Ansari, W.; Adetunji, H.; Oskrochi, R. Food and mental health: Relationship between food and perceived stress and depressive symptoms among university students in the United Kingdom. *Cent. Eur. J. Public Health* 2014, 22, 90–97. [CrossRef]

21. Yu, B.; He, H.; Zhang, Q.; Wu, H.; Du, H.; Liu, L.; Wang, C.; Shi, H.; Xia, Y.; Guo, X.; et al. Soft drink consumption is associated with depressive symptoms among adults in China. *J. Affect. Disord.* 2015, 172, 422–427. [CrossRef]

22. Westover, A.N.; Marangell, L.B. A cross-national relationship between sugar consumption and major depression? *Depress. Anxiety* 2002, 16, 118–120. [CrossRef]

23. Singh, G.M.; Micha, R.; Khatibzadeh, S.; Lim, S.; Ezzati, M.; Mozaffarian, D. Estimated Global, Regional, and National Disease Burdens Related to Sugar-Sweetened Beverage Consumption in 2010. *Circulation* 2015, 132, 639–666. [CrossRef]

24. Malik, V.S.; Li, Y.; Pan, A.; De Koning, L.; Schernhammer, E.; Willett, W.C.; Hu, F.B. Long-Term Consumption of Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Mortality in US Adults. *Circulation* 2019, 139, 2113–2125. [CrossRef]

25. Mullee, A.; Romaguera, D.; Pearson-Stuttard, J.; Viallon, V.; Stepien, M.; Freisling, H.; Fagherazzi, G.; Mancini, F.R.; Boutron-Ruault, M.C.; Kuhn, T.; et al. Association Between Soft Drink Consumption and Mortality in 10 European Countries. *JAMA Intern. Med.* 2019, 179, 1479–1490. [CrossRef]

26. Gardener, H.; Rundek, T.; Markert, M.; Wright, C.B.; Elkind, M.S.V.; Sacco, R.L. Diet Soft Drink Consumption is Associated with an Increased Risk of Vascular Events in the Northern Manhattan Study. *J. Gen. Intern. Med.* 2012, 27, 1120–1126. [CrossRef]

27. Mueller, N.T.; Odegaard, A.; Anderson, K.; Yuan, J.M.; Gross, M.; Koh, W.P.; Pereira, M.A. Soft drink and juice consumption and risk of pancreatic cancer: The Singapore Chinese Health Study. *Cancer Epidemiol. Biomark. Prev.* 2010, 19, 447–455. [CrossRef]

28. Pacheco, L.S.; Lacey, J.V.; Martinez, M.E.; Lemus, H.; Araneta, M.R.G.; Sears, D.D.; Talavera, G.A.; Anderson, C.A.M. Sugar-Sweetened Beverage Intake and Cardiovascular Disease Risk in the California Teachers Study. *J. Am. Heart Assoc.* 2020, 9, e014883. [CrossRef]

29. Hu, D.; Cheng, L.; Jiang, W. Sugar-sweetened beverages consumption and the risk of depression: A meta-analysis of observational studies. *J. Affect. Disord.* 2019, 245, 348–355. [CrossRef]

30. Milajerdi, A.; Larjani, B.; Esmailzadeh, A. Sweetened Beverages Consumption and Pancreatic Cancer: A Meta-Analysis. *Nutr. Cancer* 2019, 71, 375–384. [CrossRef]

31. Qin, P.; Li, Q.; Zhao, Y.; Chen, Q.; Sun, X.; Liu, Y.; Li, H.; Wang, T.; Chen, X.; Zhou, Q.; et al. Sugar and artificially sweetened beverages and risk of obesity, type 2 diabetes mellitus, hypertension, and all-cause mortality: A dose–response meta-analysis of prospective cohort studies. *Eur. J. Epidemiol.* 2020, 35, 665–671. [CrossRef]

32. Anderson, J.J.; Gray, S.R.; Welsh, P.; Mackay, D.F.; Celis-Morales, C.A.; Lyall, D.M.; Forbes, J.; Sattar, N.; Gill, J.M.R.; Pell, J.P. The associations of sugar-sweetened, artificially sweetened and naturally sweet juices with all-cause mortality in 198,285 UK Biobank participants: A prospective cohort study. *BMJ Med.* 2020, 19, 97. [CrossRef]

33. Zhang, Y.-B.; Chen, J.-X.; Jiang, Y.-W.; Xia, P.-F.; Pan, A. Association of sugar-sweetened beverage and artificially sweetened beverage intakes with mortality: An analysis of US National Health and Nutrition Examination Survey. *Eur. J. Nutr.* 2020, 60, 1945–1955. [CrossRef]

34. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Ann. Intern. Med.* 2009, 151, 264–269, W64. [CrossRef]

35. Higgins, J.; Green, S. *Cochrane Reviewers’ Handbook 5.0.1* (Updated September 2008); The Cochrane Library/Wiley: Chichester, UK, 2008.

36. Wells, G.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 10 November 2021).

37. Greenland, S.; Longnecker, M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *Am. J. Epidemiol.* 1992, 135, 1301–1309. [CrossRef]

38. Eshak, E.S.; Iso, H.; Kokubo, Y.; Saito, I.; Yamagishi, K.; Inoue, M.; Tsugane, S. Soft drink intake in relation to incident ischemic heart disease, stroke, and stroke subtypes in Japanese men and women: The Japan Public Health Centre-based study cohort. *Am. J. Clin. Nutr.* 2012, 96, 1390–1397. [CrossRef]

39. Larsson, S.C.; Akesson, A.; Wolk, A. Sweetened beverage consumption is associated with increased risk of stroke in women and men. *J. Nutr.* 2014, 144, 856–860. [CrossRef]

40. Chazelas, E.; Srou, B.; Desmetz, E.; Kesse-Guyot, E.; Julia, C.; Deschamps, V.; Druenes-Pecollo, N.; Galan, P.; Hercberg, S.; Latino-Martel, P.; et al. Sugary drink consumption and risk of cancer: Results from NutriNet-Sante prospective cohort. *BMJ* 2019, 366, I2408. [CrossRef]

41. Drake, I.; Sonestedt, E.; Gullberg, B.; Ahlgren, G.; Bjartell, A.; Wallstrom, P.; Wirfalt, E. Dietary intakes of carbohydrates in relation to prostate cancer risk: A prospective study in the Malmo Diet and Cancer cohort. *Am. J. Clin. Nutr.* 2012, 96, 1409–1418. [CrossRef]

42. Holick, C.N.; Smith, S.G.; Giovannucci, E.; Michaud, D.S. Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. *Cancer Epidemiol. Biomark. Prev.* 2010, 19, 39–47. [CrossRef]

43. Inoue-Choi, M.; Robien, K.; Mariani, A.; Cerhan, J.R.; Anderson, K.E. Sugar-Sweetened Beverage Intake and the Risk of Type I and Type II Endometrial Cancer among Postmenopausal Women. *Cancer Epidemiol. Biomark. Prev.* 2013, 22, 2384–2394. [CrossRef]

44. Larsson, S.C.; Bergkvist, L.; Wolk, A. Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. *Am. J. Clin. Nutr.* 2006, 84, 1171–1176. [CrossRef]
45. Makarem, N.; Bandera, E.V.; Lin, Y.; Jacques, P.F.; Hayes, R.B.; Parekh, N. Consumption of Sugars, Sugary Foods, and Sugary Beverages in Relation to Adiposity-Related Cancer Risk in the Framingham Offspring Cohort (1991–2013). Cancer Prev. Res. 2018, 11, 347–358. [CrossRef]

46. Nomura, S.J.O.; Dash, C.; Rosenberg, L.; Yu, J.; Palmer, J.R.; Adams-Campbell, L.L. Adherence to diet, physical activity and body weight recommendations and breast cancer incidence in the Black Women’s Health Study. Int. J. Cancer 2016, 139, 2738–2752. [CrossRef]

47. Nothlings, U.; Murphy, S.P.; Wilkens, L.R.; Henderson, B.E.; Kolonel, L.N. Dietary glycemic load, added sugars, and carbohydrates as risk factors for pancreatic cancer: The Multiethnic Cohort Study. Am. J. Clin. Nutr. 2007, 86, 1495–1501. [CrossRef]

48. Schernhammer, E.S.; Hu, F.B.; Giovannucci, E.; Michaud, D.S.; Colditz, G.A.; Stampfer, M.J.; Fuchs, C.S. Sugar-sweetened soft drink consumption and risk of pancreatic cancer in two prospective cohorts. Cancer Epidemiol. Biomark. Prev. 2005, 14, 2098–2105. [CrossRef]

49. Stepien, M.; Duarte-Salles, T.; Fedirko, V.; Trichopoulou, A.; Lagiou, P.; Bamia, C.; Overvad, K.; Tjonneland, A.; Hansen, L.; Bouton-Ruault, M.C.; et al. Consumption of soft drinks and juices and risk of liver and biliary tract cancers in a European cohort. Eur. J. Nutr. 2016, 55, 7–20. [CrossRef]

50. Guo, X.; Park, Y.; Freedman, N.D.; Sinha, R.; Hollenbeck, A.R.; Blair, A.; Chen, H. Sweetened beverages, coffee, and tea and depression risk among older US adults. PLoS ONE 2014, 9, e94715. [CrossRef]

51. Knuppel, A.; Shipley, M.J.; Llewellyn, C.H.; Brunner, E.J. Sugar intake from sweet food and beverages, common mental disorder and depression: Prospective findings from the Whitehall II study. Scp. Rep. 2017, 7, 6287. [CrossRef]

52. Sanchez-Villegas, A.; Zazpe, I.; Santiago, S.; Perez-Cornago, A.; Martinez-Gonzalez, M.A.; Lahortiga-Ramos, F. Added sugars and sugar-sweetened beverage consumption, dietary carbohydrate index and depression risk in the Seguimiento Universidad de Navarra (SUN) Project. Br. J. Nutr. 2017, 119, 211–221. [CrossRef]

53. Barrington, W.E.; White, E. Mortality outcomes associated with intake of fast-food items and sugar-sweetened drinks among older adults in the Vitamins and Lifestyle (VITAL) study. Public Health Nutr. 2016, 19, 3319–3326. [CrossRef]

54. Collin, L.J.; Judd, S.; Safford, M.; Vaccarino, V.; Welsh, J.A. Association of Sugary Beverage Consumption With Mortality Risk in US Adults: A Secondary Analysis of Data From the REGARDS Study. JAMA Neto. Open 2019, 2, e193121. [CrossRef]

55. Odegaard, A.O.; Koh, W.P.; Yuan, J.M.; Pereira, M.A. Beverage habits and mortality in Chinese adults. J. Nutr. 2015, 145, 595–604. [CrossRef]

56. Paganini-Hill, A.; Kawas, C.H.; Corrada, M.M. Non-alcoholic beverage and caffeine consumption and mortality: The Leisure World Cohort Study. Prev. Med. 2007, 44, 305–310. [CrossRef]

57. De Koning, L.; Malik, V.S.; Kellogg, M.D.; Rimm, E.B.; Willett, W.C.; Hu, F.B. Sweetened Beverage Consumption, Incident Coronary Heart Disease, and Biomarkers of Risk in Men. Circulation 2012, 125, 1735–1741. [CrossRef]

58. Aeberli, I.; Gerber, P.A.; Hochuli, M.; Kohler, S.; Haile, S.R.; Gouni-Berthold, I.; Berthold, H.K.; Spinhas, G.A.; Berneis, K. Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: A randomized controlled trial. Am J. Clin. Nutr. 2011, 94, 479–485. [CrossRef]

59. Jensen, P.N.; Howard, B.V.; Best, L.G.; O’Leary, M.; Devereux, R.B.; Cole, S.A.; MacCluer, J.W.; Ali, T.; Lee, E.T.; Yeh, F.L.; et al. Associations of diet soda and non-caloric artificial sweetener use with markers of glucose and insulin homeostasis and incident diabetes: The Strong Heart Family Study. Eur. J. Clin. Nutr. 2019, 74, 322–327. [CrossRef]

60. Mozaffarian, D.; Hao, T.; Rimm, E.B.; Willett, W.C.; Hu, F.B. Changes in diet and lifestyle and long-term weight gain in women and men. N. Engl. J. Med. 2011, 364, 2392–2404. [CrossRef]

61. Strazzullo, P.; D’Elia, L.; Cairella, G.; Garbaragni, F.; Cappuccio, F.P.; Scalfi, L. Excess body weight and incidence of stroke: Meta-analysis of prospective studies with 2 million participants. Stroke 2010, 41, e418–e426. [CrossRef]

62. Goldstein, L.B.; Bushnell, C.D.; Adams, R.J.; Appel, L.J.; Braun, L.T.; Chaturvedi, S.; Creager, M.A.; Culebras, A.; Eckel, R.H.; Hart, R.G.; et al. Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42, 517–584. [CrossRef]

63. World Cancer Research Fund International. Obesity, Physical Activity and Cancer. Available online: http://www.wcrf.org/sites/default/files/Obesity-physical-activity-and-cancer-infographic.pdf (accessed on 10 November 2021).

64. Boyle, P.; Koechlin, A.; Autier, P. Sweetened carbonated beverage consumption and cancer risk. Eur. J. Cancer Prev. 2014, 23, 481–490. [CrossRef] [PubMed]

65. Genkinger, J.M.; Li, R.; Spiegelman, D.; Anderson, K.E.; Albanes, D.; Bergkvist, L.; Bernstein, L.; Black, A.; van den Brandt, P.A.; English, D.R.; et al. Coffee, tea, and sugar-sweetened carbonated soft drink intake and pancreatic cancer risk: A pooled analysis of 14 cohort studies. Cancer Epidemiol. Biomark. Prev. 2012, 21, 305–318. [CrossRef] [PubMed]

66. Maersk, M.; Belza, A.; Stødkilde-Jørgensen, H.; Ringgaard, S.; Chabanova, E.; Thomsen, H.; Pedersen, S.B.; Astrup, A.; Richelsen, B. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: A 6-mo randomized intervention study. Am. J. Clin. Nutr. 2012, 95, 283–289. [CrossRef]

67. Boyle, P.; Donohoe, C.L.; Lysaght, J.; Reynolds, J.V. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc. Nutr. Soc. 2011, 71, 181–189. [CrossRef]
69. Augustin, L.S.A.; Kendall, C.W.C.; Jenkins, D.J.A.; Willett, W.C.; Astrup, A.; Barclay, A.W.; Bjorck, I.; Brand-Miller, J.C.; Brighenti, F.; Buysen, A.E.; et al. Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). *Nutr. Metab. Cardiovasc. Dis.* 2015, 25, 795–815. [CrossRef]

70. Larsson, S.C.; Mantzoros, C.S.; Wolk, A. Diabetes mellitus and risk of breast cancer: A meta-analysis. *Int. J. Cancer* 2007, 121, 856–862. [CrossRef]

71. Shi, Z.; Taylor, A.W.; Wittert, G.; Goldney, R.; Gill, T.K. Soft drink consumption and mental health problems among adults in Australia. *Public Health Nutr.* 2010, 13, 1073–1079. [CrossRef]

72. Barros, M.B.d.A.; Lima, M.G.; de Azevedo, R.C.S.; Medina, L.B.d.P.; Lopes, C.d.S.; Menezes, P.R.; Malta, D.C. Depression and health behaviors in Brazilian adults—PNS 2013. *Rev. Saúde Pública* 2017, 51 (Suppl. 1), 8s. [CrossRef]

73. Lien, L.; Lien, N.; Heyerdahl, S.; Thoresen, M.; Bjertness, E. Consumption of Soft Drinks and Hyperactivity, Mental Distress, and Conduct Problems Among Adolescents in Oslo, Norway. *Am. J. Public Health* 2006, 96, 1815–1820. [CrossRef]

74. McInnis, C.M.; Thoma, M.V.; Gianferante, D.; Hanlin, L.; Chen, X.; Breines, J.G.; Hong, S.; Rohleder, N. Measures of adiposity predict interleukin-6 responses to repeated psychosocial stress. *Brain Behav. Immun.* 2014, 42, 33–40. [CrossRef] [PubMed]

75. Wang, J.; Light, K.; Henderson, M.; O’Loughlin, J.; Mathieu, M.E.; Paradis, G.; Gray-Donald, K. Consumption of added sugars from liquid but not solid sources predicts impaired glucose homeostasis and insulin resistance among youth at risk of obesity. *J. Nutr.* 2014, 144, 81–86. [CrossRef] [PubMed]

76. Sen, S.; Duman, R.; Sanacora, G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. *Biol. Psychiatry* 2008, 64, 527–532. [CrossRef] [PubMed]

77. Molteni, R.; Barnard, R.J.; Ying, Z.; Roberts, C.K.; Gomez-Pinilla, F. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. *Neuroscience* 2002, 112, 803–814. [CrossRef]

78. Heyward, F.D.; Walton, R.G.; Carle, M.S.; Coleman, M.A.; Garvey, W.T.; Sweatt, J.D. Adult mice maintained on a high-fat diet exhibit object location memory deficits and reduced hippocampal SIRT1 gene expression. *Neurobiol. Learn. Mem.* 2012, 98, 25–32. [CrossRef]

79. Calder, P.C.; Ahluwalia, N.; Brouns, F.; Buetler, T.; Clement, K.; Cunningham, K.; Esposito, K.; Jonsson, L.S.; Kolb, H.; Lansink, M.; et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. *Br. J. Nutr.* 2011, 106 (Suppl. 3), S5–S78. [CrossRef]

80. Kivimäki, M.; Shipley, M.J.; Batty, G.D.; Hamer, M.; Akbaraly, T.N.; Kumari, M.; Jokela, M.; Virtanen, M.; Lowe, G.D.; Ebmeier, K.P.; et al. Long-term inflammation increases risk of common mental disorder: A cohort study. *Mol. Psychiatry* 2013, 19, 149–150. [CrossRef]

81. Schwartz, N.S.; Clutter, W.E.; Shah, S.D.; Cryer, P.E. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. *J. Clin. Investig.* 1987, 79, 777–781. [CrossRef]

82. Ruanpeng, D.; Thongprayoon, C.; Cheungpasitporn, W.; Harindhanavudhi, T. Sugar and artificially sweetened beverages linked to obesity: A systematic review and meta-analysis. *QJM Int. J. Med.* 2017, 110, 513–520. [CrossRef]

83. Schwingshackl, L.; Schwedhelm, C.; Hoffmann, G.; Knüppel, S.; Iqbal, K.; Andriolo, V.; Behchthold, A.; Schlesinger, S.; Boeing, H. Food Groups and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies. *Adv. Nutr. Int. Rev.* 2017, 8, 793–803. [CrossRef] [PubMed]

84. Schwingshackl, L.; Hoffmann, G.; Lampousi, A.M.; Knüppel, S.; Iqbal, K.; Schwedhelm, C.; Behchthold, A.; Schlesinger, S.; Boeing, H. Food groups and risk of type 2 diabetes mellitus: A systematic review and meta-analysis of prospective studies. *Eur. J. Epidemiol.* 2017, 32, 363–375. [CrossRef] [PubMed]

85. Xi, B.; Huang, Y.; Reilly, K.H.; Li, S.; Zheng, R.; Barrio-Lopez, M.T.; Martinez-Gonzalez, M.A.; Zhou, D. Sugar-sweetened beverages and risk of hypertension and CVD: a dose-response meta-analysis. *Br. J. Nutr.* 2015, 113, 709–717. [CrossRef] [PubMed]

86. Makarem, N.; Bandera, E.V.; Nicholson, J.M.; Parekh, N. Consumption of Sugars, Sugary Foods, and Sugary Beverages in Relation to Cancer Risk: A Systematic Review of Longitudinal Studies. *Annu. Rev. Nutr.* 2018, 38, 17–39. [CrossRef] [PubMed]